The CXCL9, CXCL10, and CXCL11/CXCR3 axis was generally considered to have antiangiogenic effects on endothelial cells and has been reported as effective tumor angiogenesis inhibitors in some in vivo tumor models, including pancreatic cancer, breast cancer, lung cancer, and melanoma [40]. This evidence concerns the gene CXCL9 and breast cancer.